Slow buy-in: Only 3% of neurologists have written Aduhelm prescriptions so far
By
Alicia Lasek
Jul 15, 2021
Neurologists are very aware of Biogen’s newly approved Alzheimer’s drug, but few have prescribed it so far, a real-time study of the brand’s market launch has found.
Criticism, confusion and hope: new Alzheimer’s drug receives messy welcome
By
Alicia Lasek
Jun 15, 2021
Clinicians’ responses to the controversial approval of Aduhelm range between excitement and disapproval, with questions abounding on how to advise patients on treatment and the cost to patients and...